Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Humatrope ® (somatropin)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
HUMATROPE® (somatropin): Use in Patients With COVID-19 (Coronavirus disease 2019)
The use of somatropin in patients with COVID-19 has not been studied.
COVID-19 is an infectious respiratory disease caused by SARS-CoV-2, previously referred to as "2019 novel coronavirus."1
Lilly has not studied the use of Humatrope in patients with COVID-19 nor in patients at risk of contracting COVID-19.
Growth hormone should not be initiated to treat patients with acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or to patients having acute respiratory failure. 2
Dyspnoea has been reported in somatropin clinical trials and post-marketing spontaneous reports in 1%-10% of adults.2
Infectious Disease Resources for COVID-19
For current information on COVID-19, please refer to
Coronavirus disease (COVID-19) outbreak on the regional office EU WHO
COVID-19 information for children and adolescents living with endocrine conditions on the ESPE website, and
1. Naming the coronavirus disease (COVID-19) and the virus that causes it. World Health Organization. Accessed March 17, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
3. Coronavirus disease (COVID-19) outbreak. European web page of the World Health Organization. Accessed March 20, 2020. http://www.euro.who.int/en/health-topics/health-emergencies/coronavirus-covid-19
4. COVID-19 INFORMATION FOR CHILDREN AND ADOLESCENTS LIVING WITH ENDOCRINE CONDITIONS, INCLUDING TYPE 1 DIABETES MELLITUS https://www.eurospe.org/news/item/14064/COVID-19-information-for-children-and-adolescents-living-with-endocrine-conditions-including-type-1-diabetes-mellitus Accessed March 26, 2020
5. COVID-19. European Centre for Disease Prevention and Control. Accessed March 20, 2020. https://www.ecdc.europa.eu/en/novel-coronavirus-china
COVID-19 = coronavirus disease 2019
ECDC = European Centre for Disease Prevention and Control
ESPE = European Society for Paediatric Endocrinology
EU WHO = World Health Organization (European regional office)
Lilly = Eli Lilly and Company
SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2
Date of Last Review: 17 March 2020